federal_register: 2015-30931

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
2015-30931 Best Practices for Communication Between Investigational New Drug Sponsors and Food and Drug Administration During Drug Development; Draft Guidance for Industry and Review Staff; Availability Notice The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and review staff entitled "Best Practices for Communication Between IND Sponsors and FDA During Drug Development." The purpose of this guidance is to describe best practices and procedures for timely, transparent, and effective communications between investigational new drug application (IND) sponsors and FDA at critical junctures in drug development, which may facilitate earlier availability of safe and effective drugs to the American public. 2015-12-09 2015 12 https://www.federalregister.gov/documents/2015/12/09/2015-30931/best-practices-for-communication-between-investigational-new-drug-sponsors-and-food-and-drug https://www.govinfo.gov/content/pkg/FR-2015-12-09/pdf/2015-30931.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and review staff entitled "Best Practices for Communication Between IND Sponsors and FDA During Drug Development." The purpose of this...  

Links from other tables